Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

Results

Save Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial	Phase	Eligible Participant	Official Title	Drugs in Trial	Location
NCT02855944	III	Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)	ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	California, Colorado, Georgia, Maine, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action Rucaparib AG-014699, PF 01367338, CO-338, Rubraca PARP inhibitor
NCT03398655	III	Platinum resistant ovarian cancer	A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer	View Drugs	Massachusetts, Montana, New York, South Carolina, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Ofranergene Obadenovec VB-111 Endothelin promoter-apoptotic receptor gene therapy Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02091141	IIa	Advanced solid tumors with ALK mutations or high TMB	My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents	View Drugs	Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Alectinib ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802 ALK kinase inhibitor Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells
NCT02658890	IIa	Advanced solid tumors (in expansion)	A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	View Drugs	Arizona, California, Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action BMS-986205 Inhibits IDO to stimulate immune response Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02584478	IIa	Recurrent ovarian cancer	A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)	View Drugs	California, Florida, Louisiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action Anlotinib AL3818 VEGFR2/3 kinase inhibitor Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02558348	IIa	Platinum refractory or persistent ovarian cancer (< 3 prior therapies) with FGFR 1-3 alterations	A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)	View Drugs	Illinois, Utah
Drug(s) in Trial Other Drug Names Main Known Action AL3818 VEGFR and FGFR kinase inhibitor
NCT02419417	IIa	Platinum resistant or refractory ovarian cancer with BRCA1/2-mutations	A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies	View Drugs	California, Colorado, Oregon, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action BMS-986158 BET inhibitor BMS-986158 BET inhibitor Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02502266	II/III	Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutant ovarian cancer	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	View Drugs	Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Cediranib Recentin, Cediranib maleate, AZD2171 VEGFR1-3 kinase inhibitor Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor Olaparib AZD2281, Lynparza PARP inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Topotecan Hycamptamine, Hycamtin, TOPO Topoisomerase I inhibitor
NCT02839707	II/III	Platinum resistant ovarian cancer	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer	View Drugs	Alaska, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor
NCT01325441	II	Platinum resistant or refractory ovarian cancer (< 4 prior cytotoxic therapies)	A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies	View Drugs	Indiana
Drug(s) in Trial Other Drug Names Main Known Action Napabucasin cancer stemness inhibitor BBI608, BBI608 STAT3 and cancer stemness inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02554812	II	Advanced solid tumors (in ovarian expansion)	A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies	View Drugs	California, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells PD-0360324 anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 CSF1R antagonist and tumor-associated macrophage inhibitor PF-04518600 anti-OX40 antibody PF-04518600 Stimulates OX40 to increase T cell activation and immune response
NCT02832167	II	Advanced solid tumors	An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies	View Drugs	Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02785250	II	Recurrent ovarian cancer	A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer	View Drugs	California, Georgia, New York, Oregon, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Cyclophosphamide Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan DNA damaging agent DPX-Survivac survivin antigen vaccine DPX-Survivac Immune response against cancer expressing survivin Epacadostat 3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360 Inhibits IDO to stimulate immune response
NCT01851369	II	Advanced solid tumors and granulosa cell ovarian cancer (in expansion)	A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action methoxyamine TRC102 Base excision repair inhibitor Temozolomide Temodal, Temodar, Methazolastone DNA damaging agent
NCT01690468	II	Platinum resistant or persistent ovarian cancer	A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer	View Drugs	Florida
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Triciribine TCN-PM, PTX-200, tricycloside phosphate, tricyclic nucleoside, triciribine phosphate, API-2, TCN, NSC 154020, Akt/PKB Signaling Inhibitor-2, Inhibitor V, VD-0002 AKT phosphorylation inhibitor
NCT02571725	II	Recurrent ovarian cancer with germline BRCA1/2 mutations	A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer	View Drugs	Florida, New Mexico, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT02693535	II	Advanced solid tumors with defined molecular alterations (VEGFR, Bcr-abl, SRC, LYN, LCK, ALK, ROS1, MET,CDKN2A/p16, CDK4, CDK6, CSF1R, PDGFR, mTOR, TSC, ERBB2, BRAFV600E, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, BRCA1/BRCA2, ATM, POLD, POLE, highTMB)	Targeted Agent and Profiling Utilization Registry (TAPUR) Study	View Drugs	Alabama, Arizona, California, Florida, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action Axitinib Inlyta, AG-013736 Multi-targeted RTK inhibitor Bosutinib Bosulif, SKI-606 Abl and src family kinase inhibitor Cetuximab Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 EGFR antagonist Cobimetinib Cotellic, GDC-0973, XL518 MEK1 inhibitor Crizotinib c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori c-Met and ALK kinase inhibitor Dasatinib BMS-354825, Sprycel SRC and bcr-abl kinase inhibitor Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells Olaparib AZD2281, Lynparza PARP inhibitor Palbociclib PD-0332991, PD0332991, Ibrance CDK4/6 inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells Pertuzumab Perjeta, monoclonal antibody 2C4, rhuMAb2C4 HER2 dimerization inhibitor Regorafanib BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga Multi-targeted RTK inhibitor Sunitinib Sunitinib malate, Sutent VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit Temsirolimus CCI-779, Torisel mTOR inhibitor Trastuzumab Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody HER2 antagonist Vemurafenib Zelboraf, PLX4032, RO5185426 BRAF kinase inhibitor
NCT02465060	II	Advanced solid tumors with alterations in ALK, cKIT, EGFR, ERBB2 AMP, FGFR1-3, FGFR1-3 AMP, GNAQ, GNA11, MET, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, ROS1, SMO, TSC1/2	Molecular Analysis for Therapy Choice (MATCH)	View Drugs	Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Afatinib BIBW 2992 MA2, Gilotrif, Afatinib dimaleate EGFR, HER2, HER4 kinase inhibitor Copanlisib BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 pan-PI3K inhibitor Crizotinib c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori c-Met and ALK kinase inhibitor Erdafitinib pan-FGFR tyrosine kinase inhibitor JNJ-42756493 pan-FGFR kinase inhibitor Larotrectinib Trk inhibitor LOXO-101 Pan-Trk kinase inhibitor Osimertinib Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib EGFR kinase inhibitor Pertuzumab Perjeta, monoclonal antibody 2C4, rhuMAb2C4 HER2 dimerization inhibitor Sapanisertib TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128 TORC1/2 kinase inhibitor Sunitinib Sunitinib malate, Sutent VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit Trametinib Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 MEK1/2 inhibitor Trastuzumab Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody HER2 antagonist Vismodegib Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 Smoothened antagonist
NCT02628067	II	Advanced solid tumors with high MSI	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	View Drugs	California, Colorado, Florida, Maryland, Massachusetts, Minnesota, New Jersey, New Mexico, Texas
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02576444	II	Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations	A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors	View Drugs	Connecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor AZD6738 ATR kinase inhibitor Capivasertib Akt inhibitor AZD5363 pan-AKT inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT02484404	II	Platinum resistant or refractory ovarian cancer ( > 2 prior platinum therapies)	Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Cediranib Recentin, Cediranib maleate, AZD2171 VEGFR1-3 kinase inhibitor Durvalumab Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Olaparib AZD2281, Lynparza PARP inhibitor
NCT02272998	II	Advanced Solid Tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations	Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)	View Drugs	Ohio
Drug(s) in Trial Other Drug Names Main Known Action Ponatinib multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534 Multi-targeted kinase inhibitor
NCT02079740	II	Advanced solid tumors with KRAS or NRAS mutations (in expansion)	An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Navitoclax Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263 Bcl-2, Bcl-XL, and Bcl-w inhibitor Trametinib Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 MEK1/2 inhibitor
NCT01037790	II	Advanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterations	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Palbociclib PD-0332991, PD0332991, Ibrance CDK4/6 inhibitor
NCT01953926	II	Advanced solid tumors with activating HER2 mutations	An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.	View Drugs	Arizona, California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Neratinib HKI-272, PD272 EGFR, HER2, HER4 kinase inhibitor
NCT02203513	II	Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer	A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT02312245	II	Platinum resistant or refractory ovarian cancer	Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers	View Drugs	Arizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Topotecan Hycamptamine, Hycamtin, TOPO Topoisomerase I inhibitor
NCT02568267	II	Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	View Drugs	Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New Hampshire, New York, North Carolina, Ohio, Oklahoma, Oregon, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Entrectinib RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101 ALK, TRK, ROS1 kinase inhibitor
NCT02595892	II	Platinum resistant high grade serous ovarian cancer (only 1 prior therapy for platinum resistant disease)	Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer	View Drugs	Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Pennsylvania, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Berzosertib VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 ATR kinase inhibitor Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor
NCT02485990	II	Platinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane)	An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT02608684	II	Platinum resistant ovarian cancer	A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Cisplatin CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin DNA damaging agent Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02901899	II	Platinum resistant ovarian cancer	An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer	View Drugs	Illinois
Drug(s) in Trial Other Drug Names Main Known Action Guadecitabine DNA methyltransferase inhibitor SGI-110, SGI-110 DNA methylation inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02432378	II	Platinum sensitive ovarian cancer with first recurrence in peritoneal cavity	A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Alpha-DC1 vaccine Anti-tumor immune response Celecoxib Celebrex Cisplatin CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin DNA damaging agent
NCT02364713	II	Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)	A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	View Drugs	Arizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action MV-NIS oncolytic measles virus encoding thyroidal sodium iodide symporter Induces immune response and tumor cell lysis
NCT01697527	II	Advanced NY-ESO-1+ solid tumors	Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Cyclophosphamide Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan DNA damaging agent Fludarabine Fludara Oral, 2-F-ara-AMP, Beneflur DNA synthesis inhibitor NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL anti-NY-ESO-1 TCR gene-engineered lymphocytes Immune response against cancer expressing NY-ESO-1 NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine Immune response against cancer expressing NY-ESO-1
NCT02948101	II	Platinum resistant or refractory ovarian cancer	Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Cyclophosphamide Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan DNA damaging agent PD-0360324 anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 CSF1R antagonist and tumor-associated macrophage inhibitor
NCT02873975	II	Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations	A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT02608268	II	Advanced solid tumors (in expansion)	Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies	View Drugs	Maryland, Massachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action MBG453 Anti-TIM-3 Monoclonal Antibody MBG453, Anti-TIM3 Checkpoint Inhibitor MBG453 Blocks TIM-3 inhibition of T cells Spartalizumab anti-PD-1 monoclonal antibody PDR001 Blocks PD-L1/2 inhibition of T cells
NCT02834013	II	Advanced ovarian germ cell, mucinous, squamous cell, or adenocarcinoma	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	View Drugs	Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02900560	II	Platinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease)	Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	View Drugs	California, Maryland, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Oral Azacitidine CC-486 DNA methylation inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02843165	II	Advanced solid tumors with lesion treatable with radiotherapy	Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02983799	II	Platinum sensitive recurrent ovarian cancer (> 1 prior therapy)	Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy	View Drugs	Alaska, California, Colorado, Connecticut, Delaware, Florida, Illinois, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor
NCT03026062	II	Platinum resistant or refractory ovarian cancer	Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Durvalumab Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT03093155	II	Platinum resistant, refractory or persistent ovarian cancer	A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers	View Drugs	Connecticut, Maryland
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Ixabepilone Azaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B, Ixempra Microtubule stabilizer/mitotic inhibitor
NCT02354131	II	Platinum sensitive, recurrent high grade serous or endometrioid ovarian cancer	Part 1: AVANOVA1 - A Phase I Study to Evaluate the Safety and Tolerability of Bevacizumab-niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Part 2: AVANOVA2 - A Two-arm, Open-label, Phase II Randomized Study to Evaluate the Efficacy of Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Niraparib MK4827, Zejula PARP inhibitor
NCT02920996	II	Advanced solid tumors with NTRK1-3 rearrangements	A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Merestinib c-Met inhibitor LY2801653, LY2801653 Multi-targeted RTK inhibitor
NCT03073525	II	Advanced high grade serous, clear cell, or endometrioid ovarian cancer	A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers	View Drugs	Alabama, Georgia, Montana, New Hampshire, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Gemogenovatucel-T Vigil, bi-shRNA-furin/GMCSF-expressing autologous tumor cell vaccine, bi-shRNA-furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine, FANG vaccine Immune cell stimulator and TGFbeta inhibitor
NCT02587598	II	Advanced solid tumors (in expansion)	A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies	View Drugs	Arizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, Ohio, Oklahoma, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Azacytidine azacitidine, Vidaza, Mylosar, 5-AZC DNA methylation inhibitor INCB053914 pan-PIM inhibitor INCB053914 PIM1, 2, 3 inhibitor
NCT03412877	II	Advanced solid tumors	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action TCR-transduced PBL Anti-tumor immune response
NCT03414047	II	Platinum resistant or refractory high grade serous ovarian cancer	A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer	View Drugs	Arizona, California, Florida, Massachusetts, Missouri, New Hampshire, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT03147976	II	Advanced solid tumors with MET over-expression or mutation	A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) Mutations	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action AMG 337 c-Met kinase inhibitor
NCT03395080	II	Platinum resistant or refractory ovarian cancer	A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer	View Drugs	Alabama, Arizona, Florida, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action DKN-01 DKK1-neutralizing monoclonal antibody DKN-01 Dickkopf-1 (DKK1) antagonist Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03342417	II	Platinum resistant or refractory ovarian cancer	Phase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients	View Drugs	Georgia, New York
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03312114	II	Recurrent or persistent ovarian cancer (tumor amenable to radiation)	Phase II Trial of Concurrent Anti—PD-L1 and SAbR for Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (With Safety lead-in)	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells
NCT03310879	II	Advanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplifications	A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Abemaciclib Verzenio, CDK4/6 Dual Inhibitor LY2835219, LY2853219, Bemaciclib CDK4/6 inhibitor
NCT03355976	II	Recurrent clear cell ovarian cancer	BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas	View Drugs	Rhode Island
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03113487	II	Platinum resistant ovarian cancer (<4 prior cytotoxic therapies)	P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action MVA-p53 vaccine Modified Vaccinia Virus Ankara Vaccine Expressing p53, p53MVA, p53MVA vaccine Immune response against p53 tumor antigen Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03212274	II	Advanced solid tumors with IDH1 or IDH2 mutations	A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors	View Drugs	California, Connecticut, District of Columbia, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor
NCT03253679	II	Advanced solid tumors with CCNE1 AMP	A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification	View Drugs	California, Colorado, Kentucky, New York, North Carolina, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor
NCT03029611	II	Newly diagnosed stage III-IV ovarian cancer (neo-adjuvant)	A Phase II Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive Surgery	View Drugs	Washington
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent IGFBP-2 vaccine pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine Immune response against cancer expressing IGFBP-2 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03274661	II	Advanced solid tumors	Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency	View Drugs	Florida
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03146663	II	Platinum resistant high grade serous or endometrioid ovarian cancer (at least 3 prior therapies)	A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer	View Drugs	Arizona, California, Colorado, Florida, Illinois, Minnesota, Missouri, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action NUC-1031 gemcitabine ProTide, Acelarin, gemcitabine-phosphoramidate NUC-1031 Ribonucleotide reductase and DNA synthesis inhibitor
NCT03284385	II	Advanced solid tumors with SETD2 deficiency	A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies	View Drugs	California, District of Columbia, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor
NCT03300843	II	Advanced solid tumors (with resectable tumor)	A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Peptide loaded dendritic cell vaccine Anti-tumor immune response
NCT03428802	II	Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations	A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability	View Drugs	New Jersey
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT01876511	II	Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB	Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors	View Drugs	California, Maryland, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03462342	II	Recurrent ovarian cancer	Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action AZD6738 ATR kinase inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT03570619	II	Advanced solid tumors with CDK12 alterations	IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations	View Drugs	Michigan
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03565991	II	Advanced solid tumors with BRCA1/2 or ATM mutations	A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors	View Drugs	California, Georgia, Louisiana, Massachusetts, Missouri, New Jersey, New York, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells Talazoparib Talazoparib Tosylate, BMN-673, MDV3800 PARP inhibitor
NCT03579316	II	Platinum resistant or refractory ovarian cancer (PD on prior PARP inhibitor)	A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition	View Drugs	Massachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT03602586	II	Recurrent or persistent clear cell ovarian cancer	A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary	View Drugs	Alaska, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Virginia, Washington, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Epacadostat 3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360 Inhibits IDO to stimulate immune response Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03610490	II	Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma	Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action MDA-TIL autologous tumor-infiltrating lymphocytes MDA-TIL Anti-tumor immune response
NCT03651271	II	Recurrent ovarian cancer with high MSI	An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer	View Drugs	California, Texas
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03668119	II	Advanced solid tumors with high TMB	A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	View Drugs	California, Colorado, Florida, Illinois, Indiana, Minnesota, New Jersey, New York, North Carolina, Oregon, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03587311	II	Platinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancer	A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer	View Drugs	Ohio
Drug(s) in Trial Other Drug Names Main Known Action Anetumab ravtansine BAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343 ADC: anti-mesothelin + microtubule destabilizer (DM4) Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03682289	II	Recurrent ovarian cancer	Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action AZD6738 ATR kinase inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT03574779	II	Platinum resistant ovarian cancer	Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer	View Drugs	Massachusetts, Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Niraparib MK4827, Zejula PARP inhibitor TSR-042 ANB011, anti-PD-1 monoclonal antibody TSR-042 Blocks PD-L1/2 inhibition of T cells
NCT03704467	II	Platinum sensitive epithelial ovarian cancer with disease progression following maintenance treatment with a PARP inhibitor (at least 2 prior platinum therapies)	A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells Berzosertib VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 ATR kinase inhibitor Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Carboplatin Paraplatin, Novoplatinum DNA damaging agent Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03718091	II	Advanced solid cancer with ATM truncation mutations or other HR gene mutations	A Phase II Study of M6620 (VX-970) in Selected Solid Tumors	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Berzosertib VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 ATR kinase inhibitor
NCT03732950	II	Recurrent ovarian cancer	A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling	View Drugs	California, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03673124	II	Low grade serous ovarian cancer	A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum	View Drugs	Contact Research Staff
Drug(s) in Trial Other Drug Names Main Known Action Letrozole Femara Aromatase inhibitor Ribociclib Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali CDK4/6 inhibitor
NCT03657043	II	Platinum resistant ovarian cancer	Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen	View Drugs	Colorado, Florida, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action Tisotumab Vedotin ADC: anti-TF + microtubule destabilizer (MMAE)
NCT03742895	II	Advanced BRCA WT solid tumors with DNA repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+	A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer	View Drugs	Nebraska
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor
NCT03461952	II	Advanced solid tumors with POLE and/or POLD1 mutations	A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay	View Drugs	New York
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03776812	II	Platinum resistant or refractory ovarian cancer	A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	Arizona
Drug(s) in Trial Other Drug Names Main Known Action nab-Paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 Microtubule stabilizer/mitotic inhibitor Relacorilant CORT125134 GR antagonist
NCT03834220	II	Advanced solid tumors with a FGFR1, FGFR2 or FGFR3 fusion	A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3	View Drugs	Arizona, California, Florida, Louisiana, Maryland, Massachusetts, New Jersey, New York, North Carolina, Ohio, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Debiopharm 1347 CH5183284, FF284, FGFR Inhibitor Debio 1347 FGFR1-3 inhibitor
NCT03836352	II	Epithelial ovarian cancer (with tumor lesions < 5 cm)	A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.	View Drugs	New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action Cyclophosphamide Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan DNA damaging agent DPX-Survivac survivin antigen vaccine DPX-Survivac Immune response against cancer expressing survivin Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03684785	Ib/II	Advanced solid tumors	A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors	View Drugs	California, Florida, Iowa, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action AST-008 TLR9 agonist AST-008 TLR agonist and immune cell stimulator Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03717415	Ib/II	Advanced solid tumors	An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Rebastinib multitargeted tyrosine kinase inhibitor DCC-2036 Multi-targeted kinase inhibitor
NCT03684811	Ib/II	Advanced solid tumors with IDH1 mutations (inc expansion)	A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	View Drugs	Florida
Drug(s) in Trial Other Drug Names Main Known Action FT-2102 mutated IDH1 inhibitor
NCT03639246	Ib/II	Platinum resistant ovarian cancer	A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer	View Drugs	Arizona, California, Massachusetts, Missouri, Oklahoma, Oregon, Texas
Drug(s) in Trial Other Drug Names Main Known Action AVB-S6-500 GAS6 antagonist Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03601897	Ib/II	Advanced solid tumors	An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors	View Drugs	Alabama, New York, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Rebastinib multitargeted tyrosine kinase inhibitor DCC-2036 Multi-targeted kinase inhibitor
NCT03330405	Ib/II	Platinum sensitive recurrent ovarian cancer	A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors	View Drugs	Arkansas, California, District of Columbia, Massachusetts, Michigan, Minnesota, New York, Ohio, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells Talazoparib Talazoparib Tosylate, BMN-673, MDV3800 PARP inhibitor
NCT02759588	Ib/II	Platinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease)	Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)	View Drugs	California, Florida
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Carboplatin Paraplatin, Novoplatinum DNA damaging agent Docetaxel Taxotere Microtubule stabilizer/mitotic inhibitor Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor GL-ONC1 light-emitting oncolytic vaccinia virus GL-ONC1 Membrane disrupter Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02606305	Ib/II	Advanced FRalpha+ ovarian cancer	A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer	View Drugs	Massachusetts, Ohio, Oklahoma, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Mirvetuximab Soravtansine M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate ADC: anti-FOLR1 + microtubule destabilizer (DM4)
NCT02511795	Ib	Advanced solid tumors	A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours	View Drugs	Colorado, Florida, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT02649673	Ib	Platinum resistant ovarian cancer (in expansion)	Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies	View Drugs	Florida, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action LCL161 SMAC mimetic LCL161 SMAC mimetic and IAP antagonist Topotecan Hycamptamine, Hycamtin, TOPO Topoisomerase I inhibitor
NCT02751918	Ib	Platinum resistant mesothelin+ ovarian cancer	An Open-label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin 30 mg/m2 Given Every 3 Weeks in Subjects With Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer	View Drugs	California, Colorado, Connecticut, Ohio, Oklahoma, Oregon
Drug(s) in Trial Other Drug Names Main Known Action Anetumab ravtansine BAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343 ADC: anti-mesothelin + microtubule destabilizer (DM4) Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor
NCT02551185	Ib	Advanced solid tumors	A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action ACY-241 HDAC inhibitor ACY-241, histone deacetylase inhibitor ACY-241 HDAC inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02665416	Ib	Advanced solid tumors and platinum resistant ovarian cancer (in expansion)	An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients With Metastatic Solid Tumors	View Drugs	Colorado, Connecticut, Massachusetts, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Selicrelumab CD40 agonist monoclonal antibody RO7009789 Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response
NCT02994953	Ib	Advanced solid tumors	A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors	View Drugs	California, Connecticut, Florida, Louisiana, Maryland, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells NHS-IL12 M9241, immunocytokine NHS-IL12 IL-12 receptor agonist
NCT03099174	Ib	Advanced solid tumors	An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts.	View Drugs	California, Connecticut, Minnesota, Nevada, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action Abemaciclib Verzenio, CDK4/6 Dual Inhibitor LY2835219, LY2853219, Bemaciclib CDK4/6 inhibitor Xentuzumab BI-836845 IGF-1/2 antagonist
NCT03318445	Ib	Advanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)	Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Irinotecan Camptosar, Campto, Campothecin-11 Topoisomerase I inhibitor Rucaparib AG-014699, PF 01367338, CO-338, Rubraca PARP inhibitor
NCT03319628	Ib	Platinum resistant ovarian cancer (inc expansion)	A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b	View Drugs	Massachusetts, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action XMT-1536 ADC: anti-NaPi2b + microtubule destabilizer (auristatin)
NCT02304393	Ib	Advanced solid tumors (in expansion)	An Open-Label, Multicenter, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumors	View Drugs
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Selicrelumab CD40 agonist monoclonal antibody RO7009789 Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response
NCT03260322	Ib	Advanced solid tumors	A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	View Drugs	Arizona, California, Florida, Iowa, Kansas, New York, Pennsylvania, Tennessee, Virginia
Drug(s) in Trial Other Drug Names Main Known Action ASP8374 PTZ-201 Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03236935	Ib	Advanced solid tumors with high MSI or dMMR	Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action L-NMMA pan-nitric oxide synthase inhibitor, NG-monomethyl-L-arginine NOS inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03307785	Ib	Advanced solid tumors	Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer	View Drugs	Arizona, California, Florida, Ohio, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Carboplatin Paraplatin, Novoplatinum DNA damaging agent Niraparib MK4827, Zejula PARP inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor TSR-022 Blocks TIM-3 inhibition of T cells TSR-042 ANB011, anti-PD-1 monoclonal antibody TSR-042 Blocks PD-L1/2 inhibition of T cells
NCT03168061	Ib	Advanced solid tumors	A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma	View Drugs	California, Indiana, Missouri, Nevada, New York, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action NC-6300 epirubicin-incorporating micelle, epirubicin-conjugated polymer micelles, nanoparticle epirubicin, micellar nanoparticle-encapsulated epirubicin, K-912 Topoisomerase II inhibitor
NCT03206177	Ib	Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma	Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary	View Drugs	Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Galunisertib LY2157299 TGFBR1 antagonist Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03113188	Ib	Advanced solid tumors	Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors	View Drugs	Arizona, Louisiana, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action CBP501 G2 checkpoint inhibitor CBP501 G2 checkpoint inhibitor Cisplatin CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin DNA damaging agent Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03162562	Ib	Recurrent or persistent ovarian cancer	Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin	View Drugs	Florida, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Oregovomab OvaRex, Monoclonal Antibody B43.13, B43.13 Immune response against cancer expressing CA125 poly ICLC poly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLC Activates dendritic cells and induces interferon production
NCT03150810	Ib	Advanced solid tumors (inc ovarian expansion)	A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors	View Drugs	Michigan, Missouri, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Pamiparib PARP inhibitor BGB-290 PARP inhibitor Temozolomide Temodal, Temodar, Methazolastone DNA damaging agent
NCT03239145	Ib	Advanced solid tumors (inc ovarian expansion)	Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells Trebananib AMG 386 Angiopoietin 1/2 antagonist
NCT03621982	Ib	Advanced solid tumors (inc expansion)	A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors	View Drugs	California, Connecticut, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Camidanlumab Tesirine anti-CD25-PBD antibody-drug conjugate ADCT-301, ADCT-301 DNA damaging agent
NCT03589651	Ib	Advanced solid tumors (inc expansion)	A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors	View Drugs	California, Illinois, North Carolina, Pennsylvania, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action Epacadostat 3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360 Inhibits IDO to stimulate immune response INCB050465 PI3K-delta inhibitor INCB050465 PI3K delta inhibitor MGA012 anti-PD-1 monoclonal antibody MGA012, INCMGA00012 Blocks PD-L1 inhibition of T cells
NCT03586661	Ib	Recurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2 WT)(inc expansion)	A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Copanlisib BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 pan-PI3K inhibitor Niraparib MK4827, Zejula PARP inhibitor
NCT03558139	Ib	Advanced solid tumors (inc ovarian expansion)	A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy	View Drugs	Illinois, Michigan, Oklahoma, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells Hu5F9-G4 anti-CD47 monoclonal antibody Hu5F9-G4 Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis
NCT03611868	Ib	Advanced solid tumors	A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action APG-115 p53-HDM2 protein-protein interaction inhibitor APG-115, MDM2-p53 inhibitor APG-115 MDM2 inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03650348	Ib	Advanced HER2+ solid tumors (inc expansion)	A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells PRS-343 anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343 Immune response against cancer expressing HER2
NCT03695380	Ib	Platinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (inc expansion)	A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer	View Drugs	Arizona, California, Florida, Georgia, Maryland, Missouri, New York, Oklahoma, Tennessee, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Cobimetinib Cotellic, GDC-0973, XL518 MEK1 inhibitor Niraparib MK4827, Zejula PARP inhibitor
NCT03514121	Ia/Ib	Advanced solid tumors (inc ovarian expansion)	A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors	View Drugs	Arizona, California, Connecticut, Michigan, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action FPA150 anti-B7-H4 monoclonal antibody FPA150 Immune response against cancer expressing B7-H4, blocks B7-H4 inhibition of T cells
NCT03449381	Ia/Ib	Advanced solid tumors (inc expansion)	A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors	View Drugs	Connecticut, Florida, New York, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action BI 907828 MDM2 inhibitor
NCT03209401	Ia/Ib	Advanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion)	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies	View Drugs	District of Columbia
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Niraparib MK4827, Zejula PARP inhibitor
NCT03206047	I/IIb	Platinum resistant ovarian cancer	A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer	View Drugs	Arizona, California, Illinois, Kansas, Nebraska, New Jersey, New York, Ohio, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells CDX-1401 DEC-205/NY-ESO-1 fusion protein CDX-1401 Immune response against cancer expressing NY-ESO-1 Guadecitabine DNA methyltransferase inhibitor SGI-110, SGI-110 DNA methylation inhibitor
NCT03110107	I/IIa	Advanced solid tumors	Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors	View Drugs	Massachusetts, New Jersey, New York, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action BMS-986218 Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02913313	I/IIa	Advanced solid tumors	Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors	View Drugs	New Jersey, New York, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action BMS-986207 anti-TIGIT monoclonal antibody BMS-986207 Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02754141	I/IIa	Advanced solid tumors	A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors	View Drugs	Maryland, Massachusetts, New York, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action BMS-986179 anti-CD73 monoclonal antibody BMS-986179 Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03363776	I/IIa	Advanced solid tumors	Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors	View Drugs	New York
Drug(s) in Trial Other Drug Names Main Known Action BMS-986277 Undisclosed mechanism Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03519178	I/IIa	Platinum resistant ovarian cancer	Phase 1/2a Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine Therapy	View Drugs	California, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action PF-06873600 CDK inhibitor PF-06873600 pan-CDK inhibitor
NCT03435640	I/II	Advanced solid tumors	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies	View Drugs	Arizona, Connecticut, Florida, Georgia, New York, North Carolina, Oregon, Texas
Drug(s) in Trial Other Drug Names Main Known Action Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells NKTR-214 IL-2 receptor agonist NKTR-262 TLR7/8 agonist and immune cell activator
NCT03459222	I/II	Advanced solid tumors	A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	View Drugs	California, Colorado, Maryland, Missouri, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action BMS-986205 Inhibits IDO to stimulate immune response Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells Relatlimab BMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016 Blocks LAG-3 inhibition of T cells
NCT03446040	I/II	Advanced solid tumors	A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors	View Drugs	California, Colorado, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action BMS-986258 anti-TIM3 antibody BMS-986258 Blocks TIM-3 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03157128	I/II	Advanced solid tumors	A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	View Drugs	California, Colorado, Georgia, Illinois, Louisiana, Massachusetts, Michigan, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action LOXO-292 RET kinase inhibitor LOXO-292 RET-kinase inhibitor
NCT03602079	I/II	Advanced HER2+ solid tumors	A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies	View Drugs	Florida, Massachusetts, Michigan, New York, Oklahoma, Oregon, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action A166 anti-HER2 antibody-drug conjugate A166 ADC: anti-HER2 + cytotoxic agent
NCT02988817	I/II	Advanced solid tumors	First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax®-AXL-ADC) in Patients With Solid Tumors	View Drugs	Arizona, California, Colorado, Connecticut, Florida, Georgia, Iowa, Massachusetts, Michigan, Minnesota, New York, North Carolina, Pennsylvania, Texas, Utah, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action HuMax-AXL-ADC anti-AXL monoclonal antibody-MMAE conjugate, anti-AXL/MMAE antibody-drug conjugate ADC: anti-Axl + microtubule destabilizer (MMAE)
NCT03407976	I/II	Advanced solid tumors with high MSI or dMMR	A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)	View Drugs	Utah
Drug(s) in Trial Other Drug Names Main Known Action Apatinib YN968D1, Aitan, ATAN, Rivoceranib c-Met/VEGFR2 kinase inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03564340	I/II	Platinum resistant or refractory ovarian cancer	A Phase 1/2 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer	View Drugs	Massachusetts, New York, Ohio, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Cemiplimab anti-PD-1 monoclonal antibody REGN2810, anti-PD-1 monoclonal antibody REGN2810 Blocks PD-L1/2 inhibition of T cells REGN4018 Immune response against cancer expressing MUC16 (CA125)
NCT03013491	I/II	Advanced solid tumors	An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas	View Drugs	Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action CX-072 Blocks PD-L1 inhibition of T cells Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Vemurafenib Zelboraf, PLX4032, RO5185426 BRAF kinase inhibitor
NCT03162627	I/II	Recurrent ovarian cancer with Ras pathway alterations or PARP inhibitor resistance	Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor Selumetinib AZD6244, ARRY-142886 MEK inhibitor
NCT03251924	I/II	Advanced solid tumors	A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors	View Drugs	Massachusetts, New Jersey, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action BMS-986226 anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226 Stimulates ICOS to increase T cell activity and immune response Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02587962	I/II	Advanced solid tumors	A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors	View Drugs	California, Maryland, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Birinapant Smac Mimetic TL32711, TL32711 SMAC mimetic and IAP antag